Single-dose oral zoliflodacin was non-inferior to ceftriaxone plus azithromycin for urogenital gonorrhoea
A phase 3 open-label trial at 17 clinics in five countries including Thailand randomized people aged 12+ with suspected uncomplicated urogenital gonorrhoea 2:1 to single oral zoliflodacin 3 g (621) or IM ceftriaxone 500 mg plus oral azithromycin 1 g (309). Day 6±2 microbiological cure in microbiological ITT was 90.9% (460/506) versus 96.2% (229/238). The comparator-minus-zoliflodacin difference was 5.3%, with upper 95% CI 8.6%, below the 12% margin. Events were mostly mild/moderate and no serious events occurred.
Thai researchersRossaphorn Kittiyaowamarn; Nittaya Phanuphak